NEWS DETAIL

Coronavirus Vaccine Testing Begins at 4 More Centers

07/30/2020 - The Government of São Paulo starts this week the clinical tests of the coronavirus vaccine in four new research centers. The immunizing potential is in the final stages of research through a partnership between the Butantan Institute and the pharmaceutical company Sinovac Life Science.

The testing coordinated by Butantan will have the participation of 9 thousand volunteers and should be completed between the end of October and the beginning of November. Of the 12 research centers selected in Brazil, the Instituto de Infectologia Emílio Ribas and the HC (Hospital das Clínicas) of the Ribeirão Preto Medical School at USP will start their research on Thursday (30). The next day, it is the turn of the Municipal University of São Caetano do Sul and the Center for Research and Development of Pharmaceuticals at UFMG (Federal University of Minas Gerais).

Emílio Ribas and the UFMG Center will have 852 participants each. The Municipal University of São Caetano do Sul will have 652 volunteers, in addition to another 500 at the Ribeirão Preto HC.

The first center to test Coronavac in volunteers was the HC of the Faculty of Medicine of USP, in the capital, last Tuesday (21). The third phase of testing at HC in São Paulo is aimed at 890 volunteers. The start of tests at the other centers will be announced in the coming days.

The immunizer developed by Sinovac Life Science is one of the most promising in the world because it uses technology already known and widely applied in other vaccines. The Butantan Institute believes that its incorporation into the health system should occur more easily. The Asian laboratory has already carried out tests on around 1,000 volunteers in China, in phases 1 and 2. Before, the experimental model applied to monkeys showed expressive results in terms of the immune response against the coronavirus.

The pharmaceutical company provided Butantan with doses of the vaccine to carry out phase 3 clinical tests on volunteers in Brazil, with the aim of demonstrating its efficacy and safety.

If the vaccine is approved, Sinovac and Butantan will sign a technology transfer agreement for scale production and free supply to SUS. The next steps will be the registration of the immunizer by Anvisa (National Health Surveillance Agency) and distribution throughout Brazil.

Below, the list of the 12 study centers that will participate in the final research phase of the coronavirus vaccine:

Hospital das Clínicas, Faculty of Medicine, USP

Emílio Ribas Institute of Infectious Diseases

Hospital Israelita Albert Einstein

Municipal University of São Caetano do Sul

Unicamp Hospital of Clinics

Medical School of São José do Rio Preto

Hospital das Clínicas, Faculty of Medicine, USP, Ribeirão Preto

University of Brasilia

National Institute of Infectious Diseases Evandro Chagas de Fiocruz (RJ)

Federal University of Minas Gerais

São Lucas Hospital, PUC, Rio Grande do Sul

Hospital das Clínicas, Federal University of Paraná